Skip to Content

Research

Cottage Health Research Institute

For more information on past and current research projects and collaborations at Cottage Health, visit the Cottage Research Institute webpage.

The Cottage Pulmonary Hypertension Center plays and instrumental in the development of several new drugs for treating pulmonary hypertension, a condition in which blood vessels in the lungs become blocked or damaged, making it harder for blood to flow through the lungs to pick up oxygen.

Sponsored Clinical Trials

A Phase IIIb, Multicenter, Open-Label Study of Patients with Pulmonary Arterial Hypertension Treated with Iloprost (Inhalation) Evaluating Safety and Inhalation Times When Converting from Power Disc-6 to Power Disc-15 with the I-Neb AAD

  • Sponsor: Actelion Pharmaceuticals US, Inc.
  • Status: Closed
  • IRB#: 08-57'

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Event-Driven, Phase III Study to Assess the Effects of ACT-064992 (an Endothelin Antagonistic Drug) on Morbidity and Mortality in Patients with Symptomatic Pulmonary Arterial Hypertension (PAH)

  • Sponsor: Actelion Pharmaceuticals US, Inc.: AC-055-302
  • Status: Closed
  • IRB#: 08-58'

SERAPHIN: Long-Term Single-Arm Open-Label Extension Study to Assess the Safety and Tolerability of ACT-064992 in Patients with Symptomatic Pulmonary Arterial Hypertension

  • Sponsor: Actelion Pharmaceuticals US, Inc.: AC-055-303
  • Status: Closed
  • IRB#: 08-59'

Registry to Prospectively Evaluate Use of Ventavis in Patients with Pulmonary Arterial Hypertension (RESPIRE Registry)

  • Sponsor: Actelion Pharmaceuticals US, Inc.
  • Status: Closed
  • IRB#: 09-41'

ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension

  • Sponsor: Gilead Sciences, Inc.
  • Status: Closed
  • IRB#: 09-42'

Registry to PROSPECTively Describe Use of Epoprostenol for Injection ("RTS Epoprostenol") in Patients with Pulmonary Arterial Hypertension

  • Actelion Pharmaceuticals US, Inc.
  • Status: Closed
  • IRB#: 11-27'

A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated with Tyvaso (Treprostinil) Inhalation Solution (ASPIRE)

  • Sponsor: United Therapeutics Corp.
  • Status: Closed
  • IRB#: 12-2'

A Phase IV, Prospective, Single-Arm, Open-Label Study to Measure Outcomes in Patients with Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)

  • Sponsor: Bayer HealthCare
  • Status: Closed
  • IRB#: 14-44

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Ubenimex in Patients with Pulmonary Arterial Hypertension (WHO Group 1)

  • Sponsor: Eiger BioPharmaceuticals, Inc.
  • Status: Closed
  • IRB#: 16-10

A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of Ubenimex in Patients with Pulmonary Arterial Hypertension (WHO Group 1)

  • Sponsor: Eiger BioPharmaceuticals, Inc.
  • Status: Closed
  • IRB#: 16-86

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Compare the Efficacy and Safety of Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) with Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects with Pulmonary Arterial Hypertension

  • Sponsor: United Therapeutics Corp.
  • Status: Closed
  • IRB#: 16-98

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR Added-on to Treprostinil, Inhaled (Tyvaso) in Subjects with Pulmonary Arterial Hypertension (BEAT)

  • Sponsor: Lung Biotechnology, Inc.
  • Status: Active
  • IRB#: 14-18

OPUS Registry: US-based, observational, drug registry of Opsumit (macitentan) new users in clinical practice

  • Sponsor: Actelion
  • Status: Active
  • IRB#: 14-48

Pulmonary Hypertension Association Registry (PHAR)

  • Sponsor: Pulmonary Hypertension Association
  • Status: Active
  • IRB#: 15-31do

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease (INCREASE 201)

  • Sponsor: United Therapeutics Corp.
  • Status: Active
  • IRB#: 16-64

Pulmonary Arterial Hypertension: Selexipag - the Users Drug Registry (SPHERE)

  • Sponsor: Actelion
  • Status: Active
  • IRB#: 16-75

An Open-Label Extension study of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease (INCREASE 202)

  • Sponsor: United Therapeutics Corp.
  • Status: Active
  • IRB#: 16-87

ADAPT – A Patient Registry of the Real-world Use of Orenitram®

  • Sponsor: United Therapeutics Corporation
  • Status: Active
  • IRB#: 17-23

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects with Pulmonary Hypertension (PH) in Heart Failure with Preserved Ejection Fraction (HFpEF)

  • Sponsor: United Therapeutics Corp.
  • Status: Active
  • IRB#: 17-24

An Open-label Extension Study of Oral Treprostinil in Subjects with Pulmonary Hypertension (PH) Associated with Heart Failure with Preserved Ejection Fraction (HFpEF) - A Long-Term Follow-up to Study TDE-HF-301

  • Sponsor: United Therapeutics Corp.
  • Status: Active
  • IRB#: 17-25

Orpheus (OPsumit Historical USers cohort study) Multicenter, retrospective chart review of first-time Opsumit® (macitentan) users in the United States

  • Sponsor: Actelion Pharmaceuticals Ltd.
  • Status: Active
  • IRB#: 17-57

Investigator Initiated Studies

Non-invasive Cardiac Output Monitoring in Pulmonary Hypertension

  • Residents: Yuri Matusov; Natalie Achamallah
  • Status: Active
  • IRB#: 16-61r

Cottage Health Research Institute

Cottage Health Research Institute

Office of Research
Santa Barbara Cottage Hospital
P.O. Box 689
Santa Barbara, CA 93102

Phone: 805-324-9260

E-mail: CHRI@sbch.org

Pulmonary Hypertension Support Group

Pulmonary Hypertension Patient

Cottage Health's Pulmonary Hypertension Support Group allow you to participate in educational sessions, receive updates on medications, and get peer support & inspiration from others living with PH. Meetings are held each quarter. For more information, call 805-898-8840.